Journal ArticleDOI
Bacteriocins — a viable alternative to antibiotics?
TLDR
Although the application of specific bacteriocins might be curtailed by the development of resistance, an understanding of the mechanisms by which such resistance could emerge will enable researchers to develop strategies to minimize this potential problem.Abstract:
Solutions are urgently required for the growing number of infections caused by antibiotic-resistant bacteria. Bacteriocins, which are antimicrobial peptides produced by certain bacteria, might warrant serious consideration as alternatives to traditional antibiotics. These molecules exhibit significant potency against other bacteria (including antibiotic-resistant strains), are stable and can have narrow or broad activity spectra. Bacteriocins can even be produced in situ in the gut by probiotic bacteria to combat intestinal infections. Although the application of specific bacteriocins might be curtailed by the development of resistance, an understanding of the mechanisms by which such resistance could emerge will enable researchers to develop strategies to minimize this potential problem.read more
Citations
More filters
Journal ArticleDOI
Post-Antibiotic Gut Mucosal Microbiome Reconstitution Is Impaired by Probiotics and Improved by Autologous FMT.
Jotham Suez,Niv Zmora,Niv Zmora,Gili Zilberman-Schapira,Uria Mor,Mally Dori-Bachash,Stavros Bashiardes,Maya Zur,Dana Regev-Lehavi,Rotem Ben-Zeev Brik,Sara Federici,Max Horn,Yotam Cohen,Andreas E. Moor,David Zeevi,Tal Korem,Eran Kotler,Alon Harmelin,Shalev Itzkovitz,Nitsan Maharshak,Nitsan Maharshak,Oren Shibolet,Oren Shibolet,Meirav Pevsner-Fischer,Hagit Shapiro,Itai Sharon,Zamir Halpern,Zamir Halpern,Eran Segal,Eran Elinav +29 more
TL;DR: Collectively, potential post-antibiotic probiotic benefits may be offset by a compromised gut mucosal recovery, highlighting a need of developing aFMT or personalized probiotic approaches achieving mucosal protection without compromising microbiome recolonization in the antibiotics-perturbed host.
Journal ArticleDOI
Phage cocktails and the future of phage therapy
TL;DR: This review considers phage therapy that can be used for treating bacterial infections in humans, domestic animals and even biocontrol in foods, and explores a regulatory framework for such an approach based on an influenza vaccine model.
Journal ArticleDOI
Bacteriocins of lactic acid bacteria: extending the family
TL;DR: This review focuses on the various types of bacteriocins that can be found in LAB and the organization and regulation of the gene clusters responsible for their production and biosynthesis, and considers the food applications of the prototype bacteriOCins from LAB.
Journal ArticleDOI
Metabolic potential of endophytic bacteria
TL;DR: The bacterial endophytic microbiome promotes plant growth and health and beneficial effects are in many cases mediated and characterized by metabolic interactions as discussed by the authors, however, further research is needed to make use of beneficial plant-microbe interactions and to reduce pathogen infestation as well as to reveal novel bioactive substances of commercial interest.
Journal ArticleDOI
Antibiotic alternatives: the substitution of antibiotics in animal husbandry?
TL;DR: It is hard to conclude that the alternatives might substitute antibiotics in veterinary medicine in the foreseeable future, but prudent use of antibiotics and the establishment of scientific monitoring systems are the best and fastest way to limit the adverse effects of the abused antibiotics and to ensure the safety of animal-derived food and environment.
References
More filters
Journal ArticleDOI
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Zeneng Wang,Elizabeth Klipfell,Brian J. Bennett,Robert A. Koeth,Bruce S. Levison,Brandon DuGar,Ariel E. Feldstein,Earl B. Britt,Xiaoming Fu,Yoon-Mi Chung,Yuping Wu,Phil Schauer,Jonathan D. Smith,Hooman Allayee,W.H. Wilson Tang,Joseph A. DiDonato,Aldons J. Lusis,Stanley L. Hazen +17 more
TL;DR: Discovery of a relationship between gut-flora-dependent metabolism of dietary phosphatidylcholine and CVD pathogenesis provides opportunities for the development of new diagnostic tests and therapeutic approaches for atherosclerotic heart disease.
Journal ArticleDOI
Gut Microbiota in Health and Disease
TL;DR: The advances in modeling and analysis of gut microbiota will further the authors' knowledge of their role in health and disease, allowing customization of existing and future therapeutic and prophylactic modalities.
Journal ArticleDOI
Bacteriocins: developing innate immunity for food
TL;DR: Bacteriocins are bacterially produced antimicrobial peptides with narrow or broad host ranges that can be used to confer a rudimentary form of innate immunity to foodstuffs, helping processors extend their control over the food flora long after manufacture.
Journal ArticleDOI
Ribosomally synthesized and post-translationally modified peptide natural products: Overview and recommendations for a universal nomenclature
Paul G. Arnison,Mervyn J. Bibb,Gabriele Bierbaum,Albert A. Bowers,Tim S. Bugni,Grzegorz Bulaj,Julio A. Camarero,Dominic J. Campopiano,Gregory L. Challis,Jon Clardy,Paul D. Cotter,David J. Craik,Michael J. Dawson,Elke Dittmann,Stefano Donadio,Pieter C. Dorrestein,K. D. Entian,Michael A. Fischbach,John S. Garavelli,Ulf Göransson,Christian W. Gruber,Daniel H. Haft,Thomas Hemscheidt,Christian Hertweck,Colin Hill,Alexander R. Horswill,Marcel Jaspars,Wendy L. Kelly,Judith P. Klinman,Oscar P. Kuipers,A. James Link,Wen Liu,Mohamed A. Marahiel,Douglas A. Mitchell,Gert N. Moll,Bradley S. Moore,Rolf Müller,Satish K. Nair,Ingolf F. Nes,Gillian E. Norris,Baldomero M. Olivera,Hiroyasu Onaka,Mark L. Patchett,Joern Piel,Joern Piel,Martin J. T. Reaney,Sylvie Rebuffat,R. Paul Ross,Hans-Georg Sahl,Eric W. Schmidt,Michael E. Selsted,Konstantin Severinov,Ben Shen,Kaarina Sivonen,Leif Smith,Torsten Stein,Roderich D. Süssmuth,John R. Tagg,Gong-Li Tang,Andrew W. Truman,John C. Vederas,Christopher T. Walsh,Jonathan D. Walton,Silke C. Wenzel,Joanne M. Willey,Wilfred A. van der Donk +65 more
TL;DR: This review presents recommended nomenclature for the biosynthesis of ribosomally synthesized and post-translationally modified peptides (RiPPs), a rapidly growing class of natural products.
Journal ArticleDOI
RNA therapeutics: beyond RNA interference and antisense oligonucleotides
TL;DR: Three RNA-based therapeutic technologies exploiting various oligonucleotides that bind to RNA by base pairing in a sequence-specific manner yet have different mechanisms of action and effects are discussed.
Related Papers (5)
Ribosomally synthesized and post-translationally modified peptide natural products: Overview and recommendations for a universal nomenclature
Paul G. Arnison,Mervyn J. Bibb,Gabriele Bierbaum,Albert A. Bowers,Tim S. Bugni,Grzegorz Bulaj,Julio A. Camarero,Dominic J. Campopiano,Gregory L. Challis,Jon Clardy,Paul D. Cotter,David J. Craik,Michael J. Dawson,Elke Dittmann,Stefano Donadio,Pieter C. Dorrestein,K. D. Entian,Michael A. Fischbach,John S. Garavelli,Ulf Göransson,Christian W. Gruber,Daniel H. Haft,Thomas Hemscheidt,Christian Hertweck,Colin Hill,Alexander R. Horswill,Marcel Jaspars,Wendy L. Kelly,Judith P. Klinman,Oscar P. Kuipers,A. James Link,Wen Liu,Mohamed A. Marahiel,Douglas A. Mitchell,Gert N. Moll,Bradley S. Moore,Rolf Müller,Satish K. Nair,Ingolf F. Nes,Gillian E. Norris,Baldomero M. Olivera,Hiroyasu Onaka,Mark L. Patchett,Joern Piel,Joern Piel,Martin J. T. Reaney,Sylvie Rebuffat,R. Paul Ross,Hans-Georg Sahl,Eric W. Schmidt,Michael E. Selsted,Konstantin Severinov,Ben Shen,Kaarina Sivonen,Leif Smith,Torsten Stein,Roderich D. Süssmuth,John R. Tagg,Gong-Li Tang,Andrew W. Truman,John C. Vederas,Christopher T. Walsh,Jonathan D. Walton,Silke C. Wenzel,Joanne M. Willey,Wilfred A. van der Donk +65 more